Spots Global Cancer Trial Database for advanced adult primary liver cancer
Every month we try and update this database with for advanced adult primary liver cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer | NCT00274885 | Cancer | oxaliplatin management of t... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Iodine I 131 Ethiodized Oil in Preventing Recurrent Cancer in Patients Who Have Undergone Treatment for Liver Cancer | NCT00870558 | Liver Cancer | ethiodized oil iodine I 131 et... | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | NCT01730937 | Adult Primary H... Advanced Adult ... Recurrent Adult... | Sorafenib stereotactic bo... | 18 Years - | Radiation Therapy Oncology Group | |
| Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00041275 | Liver Cancer | megestrol aceta... | 20 Years - | National Cancer Institute (NCI) | |
| T900607 in Treating Patients With Unresectable Liver Cancer | NCT00054262 | Liver Cancer | T900607 | 18 Years - | National Cancer Institute (NCI) | |
| BMS-247550 in Treating Patients With Liver or Gallbladder Cancer | NCT00023946 | Adult Primary C... Adult Primary H... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Localized Extra... Localized Gallb... Localized Resec... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | ixabepilone laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) | NCT00077142 | Liver Cancer | TAC-101 | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed | NCT00006006 | Liver Cancer | recombinant int... thalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Celecoxib and Erlotinib in Treating Patients With Liver Cancer | NCT00293436 | Liver Cancer | celecoxib erlotinib hydro... adjuvant therap... | 18 Years - | University of California, San Francisco | |
| Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer | NCT00107536 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery | NCT00873002 | Liver Cancer | panobinostat sorafenib tosyl... | 18 Years - | Case Comprehensive Cancer Center | |
| PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer | NCT02088775 | Adult Primary H... Advanced Adult ... Metastatic Extr... Recurrent Adult... Recurrent Extra... Stage D Adult P... Unspecified Adu... | PET scan CT Scan hepatic artery ... | 18 Years - | Fox Chase Cancer Center | |
| Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer | NCT00073905 | Extrahepatic Bi... Gallbladder Can... Liver Cancer Pain | capecitabine pl... | 18 Years - 80 Years | Swiss Group for Clinical Cancer Research | |
| Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00777894 | Liver Cancer | 3-dimensional c... intensity-modul... stereotactic bo... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery | NCT00532740 | Liver Cancer Metastatic Canc... | Yttrium Y 90 gl... | 18 Years - | Northwestern University | |
| Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer | NCT00003427 | Anal Cancer Colorectal Canc... Esophageal Canc... Extrahepatic Bi... Gallbladder Can... Gastric Cancer Gastrointestina... Liver Cancer Pancreatic Canc... Small Intestine... | irinotecan hydr... oxaliplatin | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer | NCT00009893 | Extrahepatic Bi... Gallbladder Can... Liver Cancer | fluorouracil gemcitabine hyd... leucovorin calc... | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | NCT02072356 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | yttrium Y 90 gl... laboratory biom... TheraSphere | 8 Years - | Ohio State University Comprehensive Cancer Center | |
| Celecoxib and Erlotinib in Treating Patients With Liver Cancer | NCT00293436 | Liver Cancer | celecoxib erlotinib hydro... adjuvant therap... | 18 Years - | University of California, San Francisco | |
| Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder | NCT00085410 | Adenocarcinoma ... Adenocarcinoma ... Advanced Adult ... Gastrointestina... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | bortezomib | 18 Years - | National Cancer Institute (NCI) | |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00082823 | Cancer | ziv-aflibercept | 18 Years - 120 Years | Regeneron Pharmaceuticals | |
| Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum | NCT00005860 | Cancer | floxuridine leucovorin calc... oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer | NCT00003439 | Cancer | recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers | NCT01229111 | Adult Primary C... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Localized Unres... Periampullary A... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | cediranib malea... oxaliplatin leucovorin calc... fluorouracil | 18 Years - | National Cancer Institute (NCI) | |
| Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity | NCT00003548 | Cancer | aminocamptothec... | 18 Years - | NYU Langone Health | |
| Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00514228 | Liver Cancer | sunitinib malat... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies | NCT01643499 | Acinar Cell Ade... Adenocarcinoma ... Adenocarcinoma ... Adult Primary C... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Diffuse Adenoca... Duct Cell Adeno... Intestinal Aden... Localized Unres... Metastatic Carc... Metastatic Extr... Mixed Adenocarc... Mucinous Adenoc... Mucinous Adenoc... Newly Diagnosed... Signet Ring Ade... Signet Ring Ade... Stage III Pancr... Stage IIIA Colo... Stage IIIA Gall... Stage IIIA Gast... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Gall... Stage IIIB Gast... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Gast... Stage IIIC Rect... Stage IV Gastri... Stage IV Pancre... Stage IVA Colon... Stage IVA Gallb... Stage IVA Recta... Stage IVB Colon... Stage IVB Gallb... Stage IVB Recta... Unresectable Ex... | oxaliplatin irinotecan hydr... leucovorin calc... fluorouracil laboratory biom... | 18 Years - | University of Chicago | |
| Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors | NCT00093444 | Liver Cancer Metastatic Canc... | lyso-thermosens... radiofrequency ... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer | NCT00604721 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | selumetinib pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | NCT00031681 | Advanced Adult ... Carcinoma of th... Estrogen Recept... Extensive Stage... Gastrointestina... HER2-negative B... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Progesterone Re... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Borde... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Endom... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Border... Stage IV Breast... Stage IV Colon ... Stage IV Endome... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Cervi... Stage IVB Cervi... Triple-negative... Unresectable Ex... Unresectable Ga... Unspecified Adu... Untreated Metas... | 7-hydroxystauro... irinotecan hydr... diagnostic labo... | 18 Years - | National Cancer Institute (NCI) | |
| Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | NCT01666756 | Adult Primary H... Advanced Adult ... Advanced Adult ... BCLC Stage B Ad... BCLC Stage C Ad... | Chinese herbal ... sorafenib tosyl... laboratory biom... pharmacological... | 18 Years - | City of Hope Medical Center | |
| Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00335829 | Liver Cancer | bevacizumab chemotherapy embolization th... hepatic artery ... | 18 Years - 120 Years | Yale University | |
| Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00335829 | Liver Cancer | bevacizumab chemotherapy embolization th... hepatic artery ... | 18 Years - 120 Years | Yale University | |
| Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant | NCT01194206 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | stereotactic bo... | 18 Years - 70 Years | Case Comprehensive Cancer Center | |
| Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00530010 | Liver Cancer | yttrium Y 90 gl... | 18 Years - | Northwestern University | |
| Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma | NCT00057980 | Liver Cancer | celecoxib epirubicin hydr... | 18 Years - | Northwestern University | |
| Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer | NCT00253708 | Cancer | management of t... massage therapy pain therapy psychosocial as... quality-of-life... | 18 Years - 120 Years | Beth Israel Deaconess Medical Center | |
| Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma | NCT00057980 | Liver Cancer | celecoxib epirubicin hydr... | 18 Years - | Northwestern University | |
| T900607 in Treating Patients With Unresectable Liver Cancer | NCT00054262 | Liver Cancer | T900607 | 18 Years - | National Cancer Institute (NCI) | |
| Irinotecan and Capecitabine in Treating Patients With Solid Tumors | NCT00003867 | Cancer | capecitabine irinotecan hydr... | 18 Years - 120 Years | Montefiore Medical Center | |
| Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer | NCT00739167 | Liver Cancer Metastatic Canc... | 18 Years - | Northwestern University | ||
| Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors | NCT00002608 | Adrenocortical ... Brain and Centr... Head and Neck C... Liver Cancer Malignant Mesot... Pheochromocytom... Sarcoma | cisplatin doxorubicin hyd... tamoxifen citra... conventional su... radiation thera... | - 65 Years | National Cancer Institute (NCI) | |
| Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00875615 | Liver Cancer | Carboplatin Cisplatin Sorafenib | 18 Years - 120 Years | University of Miami | |
| Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy | NCT00896467 | Anal Cancer Anxiety Disorde... Breast Cancer Depression Esophageal Canc... Gallbladder Can... Gastric Cancer Kidney Cancer Liver Cancer Lung Cancer Pancreatic Canc... Small Intestine... | questionnaire a... psychosocial as... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) | NCT04000737 | Advanced Hepato... | YIV-906+Sorafen... Placebo+Sorafen... | 18 Years - | Yiviva Inc. | |
| Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer | NCT00607828 | Liver Cancer | stereotactic bo... | 19 Years - 120 Years | University of Nebraska | |
| Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis | NCT01079767 | Liver Cancer | temsirolimus | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| IMC-A12 in Treating Patients With Advanced Liver Cancer | NCT00639509 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | cixutumumab computed tomogr... contrast-enhanc... | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer | NCT00881751 | Liver Cancer | bevacizumab erlotinib hydro... sorafenib tosyl... | 18 Years - 116 Years | Medical University of South Carolina | |
| Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer | NCT00436410 | Adrenocortical ... Breast Cancer Colorectal Canc... Gastrointestina... Kidney Cancer Liver Cancer Melanoma (Skin) Ovarian Cancer Pancreatic Canc... Sarcoma | colloidal gold-... electron micros... pharmacological... conventional su... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | NCT00101036 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer | NCT00486356 | Extrahepatic Bi... Gallbladder Can... Gastric Cancer Liver Cancer Unspecified Adu... | capecitabine carboplatin epirubicin hydr... microarray anal... polymorphism an... pharmacological... | 18 Years - 120 Years | University of Nebraska | |
| Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) | NCT00071994 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | gefitinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction | NCT00047346 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | erlotinib hydro... pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer | NCT00027534 | Breast Cancer Colorectal Canc... Gallbladder Can... Gastric Cancer Head and Neck C... Liver Cancer Ovarian Cancer Pancreatic Canc... Testicular Germ... | TRICOM-CEA(6D) | 18 Years - | Duke University | |
| Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors | NCT00093444 | Liver Cancer Metastatic Canc... | lyso-thermosens... radiofrequency ... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| BMS-247550 in Treating Patients With Liver or Gallbladder Cancer | NCT00023946 | Adult Primary C... Adult Primary H... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Localized Extra... Localized Gallb... Localized Resec... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | ixabepilone laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer | NCT00087191 | Advanced Adult ... Carcinoma of th... Fallopian Tube ... Gastrointestina... Localized Extra... Localized Gallb... Localized Gastr... Localized Resec... Localized Unres... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Primary Periton... Recurrent Adult... Recurrent Adult... Recurrent Colon... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Recurrent Small... Recurrent Uteri... Regional Gastro... Small Intestine... Small Intestine... Small Intestine... Stage 0 Non-sma... Stage I Adult S... Stage I Colon C... Stage I Gastric... Stage I Non-sma... Stage I Ovarian... Stage I Ovarian... Stage I Pancrea... Stage I Rectal ... Stage I Uterine... Stage II Adult ... Stage II Colon ... Stage II Gastri... Stage II Non-sm... Stage II Ovaria... Stage II Ovaria... Stage II Pancre... Stage II Rectal... Stage II Uterin... Stage III Adult... Stage III Colon... Stage III Gastr... Stage III Ovari... Stage III Ovari... Stage III Pancr... Stage III Recta... Stage III Uteri... Stage IIIA Non-... Stage IIIB Non-... Stage IV Adult ... Stage IV Colon ... Stage IV Gastri... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Rectal... Stage IV Uterin... Unresectable Ex... Unresectable Ga... | EF5 motexafin lutet... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer | NCT00009893 | Extrahepatic Bi... Gallbladder Can... Liver Cancer | fluorouracil gemcitabine hyd... leucovorin calc... | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00335829 | Liver Cancer | bevacizumab chemotherapy embolization th... hepatic artery ... | 18 Years - 120 Years | Yale University | |
| Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | NCT00006016 | Adult Primary H... Advanced Adult ... Localized Unres... | thalidomide doxorubicin hyd... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed | NCT00006006 | Liver Cancer | recombinant int... thalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer | NCT00739167 | Liver Cancer Metastatic Canc... | 18 Years - | Northwestern University | ||
| Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer | NCT00867321 | Liver Cancer | bevacizumab sorafenib tosyl... | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant | NCT00844168 | Adult Primary H... Advanced Adult ... Localized Resec... Localized Unres... Recurrent Adult... | sorafenib tosyl... laboratory biom... | 18 Years - | University of Washington | |
| Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer | NCT00033462 | Adult Primary C... Adult Primary H... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | erlotinib hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer | NCT00238394 | Adult Primary H... Advanced Adult ... Localized Unres... | cediranib malea... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE | NCT02557503 | Advanced Adult ... | Oxaliplatin and... | 18 Years - 80 Years | Peking University Cancer Hospital & Institute | |
| Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00514228 | Liver Cancer | sunitinib malat... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| 3-Tesla MRI Response to TACE in HCC (Liver Cancer) | NCT02057874 | Adult Primary H... Advanced Adult ... Localized Resec... Localized Unres... Stage A Adult P... Stage B Adult P... | 3 Tesla Magneti... Magnevist® (Int... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer | NCT02088775 | Adult Primary H... Advanced Adult ... Metastatic Extr... Recurrent Adult... Recurrent Extra... Stage D Adult P... Unspecified Adu... | PET scan CT Scan hepatic artery ... | 18 Years - | Fox Chase Cancer Center | |
| Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma | NCT00057980 | Liver Cancer | celecoxib epirubicin hydr... | 18 Years - | Northwestern University | |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | NCT00397384 | Adenocarcinoma ... Adenocarcinoma ... Advanced Adult ... Carcinoma of th... Gastrointestina... Metastatic Gast... Metastatic Squa... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Colon... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Pancr... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Colon ... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Pancre... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Tongue Cancer Unresectable Ex... Unresectable Ga... | cetuximab erlotinib hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer | NCT00073905 | Extrahepatic Bi... Gallbladder Can... Liver Cancer Pain | capecitabine pl... | 18 Years - 80 Years | Swiss Group for Clinical Cancer Research | |
| AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer | NCT00427973 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | cediranib malea... laboratory biom... computed tomogr... dynamic contras... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | NCT00019474 | Extrahepatic Bi... Gastric Cancer Gastrointestina... Liver Cancer Pancreatic Canc... Small Intestine... | filgrastim recombinant int... fluorouracil hydroxyurea | 18 Years - 120 Years | Montefiore Medical Center | |
| Irinotecan and Capecitabine in Treating Patients With Solid Tumors | NCT00003867 | Cancer | capecitabine irinotecan hydr... | 18 Years - 120 Years | Montefiore Medical Center | |
| Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer | NCT00257426 | Liver Cancer | octreotide acet... | 18 Years - | UNC Lineberger Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
